Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS)


NEW HAVEN, Conn., July 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduviotm (oral nalbuphine ER) for prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that senior management will be attending The Twelfth London International Cough Symposium being held in London and virtually from July 13th ? 14th.

The 12th LICS brings together clinicians and scientists in a forum to discuss the latest research advances and evolving ideas relating to acute and chronic cough in clinical disease, pathophysiological mechanisms, and novel treatments for cough.

To register for the event, please click here.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

About Haduvio

Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ?-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ?- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently scheduled as a controlled substance by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Nalbuphine ER has been granted Fast Track designation by the FDA for the proposed indication of reduction of moderate to severe pruritus in adults with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
[email protected]

Media Contact
Rosalia Scampoli
914-815-1465
[email protected]

 

SOURCE Trevi Therapeutics, Inc.


These press releases may also interest you

at 15:23
Landmark Recovery of Louisville, a family-owned drug and alcohol addiction treatment provider, was ranked Kentucky's top addiction treatment center for the second consecutive year by Newsweek.  ...

at 15:20
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly...

at 15:18
Today, Pennsylvania Senator Bob Casey joined AARP Pennsylvania for a roundtable conversation highlighting how older Pennsylvanians will benefit from the Inflation Reduction Act of 2022, which was signed into law by President Biden earlier this week. ...

at 15:15
The "Global Medical Lifting Sling Market Size, Share & Trends Analysis Report, by Product (Nylon, Padded, Mesh, Canvas), by Application (Transfer, Universal, Hammock, Standing, Seating, Toilet, Bariatric), by Usage, by End-use, by Region, and Segment...

at 15:11
CiviCO, a nonprofit that cultivates civic-minded leaders, announced 29 Colorado business executives and community leaders as 2022-23 Colorado Governor's Fellows. The Colorado Governor's Fellowship program prepares private and nonprofit sector leaders...

at 15:00
Inc. magazine recently released that HumanN, an industry leader in functional nutrition and life sciences, was named for the eighth consecutive year on its annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies...



News published on 7 july 2022 at 07:30 and distributed by: